Re: Coronavirus (COVID-19) Update: FDA Recommends Inclusion of Omicron BA.4/5 Component for COVID-19 Vaccine Booster Doses
This is the best possible outcome for Novavax, since it requires a new round of trials for the BA.4/BA.5 component. This will allow Novavx to catch uo to Pfizer and Moderna if they can get their BA.4/BA.5 formulation made and into clinical testing quickly.
The other important piece is the FDA is not requiring a change to the original primary series. That means FDA will approve 2373 as a primary series, and then they will approve the booster with BA.4/BA.5 component separately.
What will be interesting to see is how well the Novavax prototype vaccine will work against BA.4/BA.5 once authorized. I hope FDA also authorizes 2373 as a booster, because the data presented by Novavax at the FDA meeting shows 3-4 shots on 2373 is very effective against these new omicron variants.